Skip to main content

Viaskin Peanut Immunotherapy Trial to Evaluate Safety, Simplicity, & Efficacy (VITESSE)

Study Overview: Researchers want to assess the efficacy and safety of a peanut patch worn on the skin (DBV712 250 μg) to induce desensitization in peanut-allergic children aged 4-7 years over a 12-month treatment period.
Who Can Participate: Peanut-allergic children aged 4-7 years who meet other inclusion and exclusion criteria
Estimated Time Commitment: Approximately 12 months
Contact Information: Jennifer_Gartrell@med.unc.edu
For more information, click here

Systems Biology of Early Atopy (SUNBEAM)

Study Overview: We want to learn more about what factors put babies and toddlers at higher risk for developing food allergies and eczema. This is an observational research study, which means we will follow you and your child from birth to 3 years to learn more about how allergies develop.
Who Can Participate: Anyone who is 18 years or older, is currently pregnant, and is planning to deliver at UNC
Estimated Time Commitment: Approximately 3 years
Contact Information: Contact the study team at sunbeam@unc.edu
For more information, click here

Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy

Study Overview: This clinical research study investigates the safety and tolerability of a peanut SLIT-tablet.
Who Can Participate:
Part Two of Study: Ages 4-65
Contact Information:
Holly Barber | (919) 962-4579 | barber25@email.unc.edu
For more information, click here

  • Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants (OUtMATCH) [more]
  • Efficacy and Safety of QGE031 (Ligelizumab) in Patients With Peanut Allergy [more]
  • A Multicenter, Open-Label, Long-Term Safety Study of AR101 Characterized Oral Desensitization Immunotherapy in Subjects Who Participated in a Prior AR101 Study  (ARC008) [more]
  • EPITOPE Open-label Extension Study to Evaluate the Long-term Clinical Benefit and Safety of DBV712 in Peanut-Allergic Children (EPOPEX) [more]
  • ADP101 for Oral Immunotherapy in Food-Allergic Children and Adults (Harmony) [more]
Interested in Participating in a Study?